Abbott Laboratories (NYSE:ABT) Stock

ABBOTT LABORATORIES

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

Goldman Sachs analyst David Roman initiated coverage on three companies, explaining that diabetes technology, including insulin pumps and continuous glucose monitors (CGMs), is expected to grow at a <a href="https://www.benzinga.com/topic/diabetes">strong double-digit pace</a>.
<h3 class="wp-block-heading">Insulet</h3>
Goldman Sachs initiated coverage on Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), citing the company to benefit from accelerating the adoption of patch pump technology as it is the only participant in the category currently.
Goldman Sachs initiated Insulet on Thursday with a Buy rating and <a href="https://www.benzinga.com/quote/PODD/analyst-ratings" target="_blank" rel="noreferrer noopener">a price target of $380</a>. The analyst highlights the company&#8217;s pipeline, which can potentially strengthen its relative position. Sustained top-line growth should support outsized adjusted EBITDA results and yield meaningful upside over the next several years.
Analyst David Roman writes, &#8220;We expect Omnipod's superior form factor and relative differentiation as a result to be the key contributor to Insulet's share capture as the insulin pump market moves into its next leg of adoption. In our view, the company is best positioned for the opportunities ahead in insulin delivery growth.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44745766/fda-approves-dexcoms-15-day-wearable-glucose-management-system-us-launch-planned-in-second-half-of-2025" rel="noreferrer noopener">FDA Approves Dexcom&#8217;s 15-Day Wearable Glucose Management System. Company Plans US Launch</a>
<h3 class="wp-block-heading">Dexcom</h3>
Goldman Sachs initiated DexCom Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">price target of $104</a>, supported by a constructive view of the company&#8217;s technology and long-term opportunity set.
Roman adds the potential upside from consumer-related adoption and strong P&amp;L leverage, which should continue through the balance of 2025.
&#8220;Taking all patient cohorts into consideration, we expect Dexcom to remain ahead in the established Type 1 and Type 2 MDI segments. And in the higher growth T2 Basal and non-insulin populations, we expect Dexcom will take some patient share from Abbott over the intermediate term, off a much lower relative base&#8230;&#8221;
The CGM market is still mainly a two-player race between Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) and DexCom, Roman says.
However, the pump market is becoming more crowded, with more companies entering and customer needs changing. Hence, Goldman Sachs reiterated Abbott as a Buy and Tandem Diabetes Care, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) as Neutral.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45321429/insulet-posts-strong-q1-results-raises-forecasts-on-momentum-in-us-and-abroad" rel="noreferrer noopener">Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad</a>
<h3 class="wp-block-heading">Beta Bionics</h3>
Goldman Sachs initiated coverage on newly listed Beta Bionics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>). The diabetes management solutions provider closed its upsized IPO of 13.8 million at $17&nbsp;per share in January, raising approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43415288/beta-bionics-announces-closing-of-234-6-million-initial-public-offering-and-full-exercise-of-under" rel="noreferrer noopener">$212.1 million in gross proceeds</a>.
The analyst initiated a Neutral rating and a <a href="https://www.benzinga.com/quote/BBNX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $16</a>, noting the company's iLet technology is well-suited for a targeted segment of the Type 1 market.
<ul class="wp-block-list">
<li>iLet is still in the early adoption phase, so its short-term growth is expected to be stronger than that of other diabetes-related companies and similar-sized medical technology firms.</li>
<li>Also, market estimates mostly reflect the growth potential over the next few years. The stock's valuation also seems to factor in this expected growth and the likelihood that the company will need to raise more money to reach break-even cash flow.</li>
</ul>
Price Action: PODD stock is up 0.14% at $324.31, BBNX stock is up 10% at $16.90, and DXCM stock is up 1% at $85.71 at the last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/05/45693375/summit-therapeutics-closely-watched-lung-cancer-study-of-ivonescimab-misses-overall-survival-endpoint" target="_blank" rel="noreferrer noopener">Summit Therapeutics&#8217; Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint</a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

News

Health Care

Initiation

Analyst Ratings

General

BBNX

DXCM

PODD

TNDM

Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges

<ul>
<li>The&nbsp;Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC)</li>
<li>Tendyne offers a new treatment option for patients who are not candidates for open-heart surgery or mitral repair</li>
<li>This approval expands Abbott's portfolio of minimally invasive structural heart therapies in the U.S.</li>
</ul>
ABBOTT PARK, Ill., May 27, 2025 /PRNewswire/ -- Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne&#x2122;&nbsp;transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease. This life-changing therapy is available for patients&nbsp;whose mitral valves are not functioning properly due to severe mitral annular calcification (MAC), a buildup of calcium within the ring-like structure (known as an annulus) that supports the&nbsp;mitral valve.
The complex nature of mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. For patients with severe MAC who are at high risk for open-heart surgery and whose mitral valve cannot be successfully repaired with the Abbott MitraClip&#x2122; device, Tendyne offers an alternative minimally invasive way to replace the valve that's leaky (mitral regurgitation) or narrowed (stenosis).

FDA Approves Abbott's Tendyne Transcatheter Mitral Valve Replacement System To Treat People With Mitral Valve Disease

WIIM

Abbott Laboratories shares are trading higher after the company announced its REFLECT real-world studies showed positive results in the reduction of risk for heart complications for people with diabetes.

<ul>
<li>New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1</li>
<li>This significant decrease is linked to the use of Libre biowearable technology compared to traditional blood glucose monitors.1</li>
<li>Results also show a reduction in hospitalization for cardiovascular complications in adults with Type 2 diabetes on insulin using Libre technology.2</li>
</ul>

Biotech

Abbott Laboratories Announces REFLECT Real-World Studies Results That Shows Use Of FreeStyle Libre Continuous Glucose Monitoring Technology Associated With Significant Reduction In Risk Of Hospitalization For Heart Complications In People With Diabetes.

An official report on May 12, 2025 reveals Representative Bruce Westerman's recent sale of Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stock, valued between $137,095 and $1,530,000. The transaction took place on May 12, 2025, as per the May filing.
At this time, Apple shares are trading up 0.22% at $211.25.
<h3>Representative's Recent Trading Activity</h3>
Over the past three years, Bruce Westerman executed 213 trades totaling over $325 thousand. The largest of these trades were in Alphabet and Amazon.com stock. Some of the key transactions the Rep. has executed recently include: 
<ul>
<li>Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>): $15,001 - $50,000 Sale</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): $1,001 - $15,000 Sale</li>
<li>adidas (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADDYY#OTC">ADDYY</a>): $1,001 - $15,000 Sale</li>
</ul>
Here is a list of Bruce Westerman's most recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-04-21</td>
</tr>
<tr>
<td>adidas</td>
<td>ADDYY</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-04-21</td>
</tr>
<tr>
<td>Adobe</td>
<td>ADBE</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-04-21</td>
</tr>
<tr>
<td>Alphabet</td>
<td>GOOGL</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-04-21</td>
</tr>
<tr>
<td>Amazon.com</td>
<td>AMZN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-04-21</td>
</tr>
</tbody>
</table>
Want to keep up with Bruce Westerman and other congressional members' stock activities? Check out our <a href="https://www.benzinga.com/gov-trades/members/bruce-westerman">government trades tool</a> for real-time updates!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

Trading Ideas

AAPL

ADDYY

Recent Filing Shows That Rep. Bruce Westerman Sold Over $137K Worth of Apple Stock

The Milken Institute's 28th annual Global Conference began on Sunday and will run through May 7 at the Beverly Hilton in Los Angeles.
What Happened: Held under the theme &#8220;Toward a Flourishing Future,&#8221; the event features more than 1,000 speakers and 5,000 attendees from over 80 countries, including CEOs, policymakers, scientists, philanthropists, and cultural icons.
Among the high-profile attendees this year are Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang, former basketball player Magic Johnson, actor Patrick Dempsey, X Corp. CEO Linda Yaccarino, former First Lady Jill Biden, Ford Philanthropy President Mary Culler, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) CEO Robert Ford and Citadel LLC founder Ken Griffin.
See Also:&nbsp;<a href="https://www.benzinga.com/25/04/45093311/not-everyone-needs-a-thousand-ai-engineers-but-for-those-who-do-zuckerberg-says-meta-will-gladly-build-it-for-a-price" target="_blank" rel="noreferrer noopener">Meta CEO Mark Zuckerberg Says AI Won't Just Be About Free Tools And Ads — Some People Will Pay A Fortune To Deploy Armies Of Digital Workers</a>
From closed-door roundtables to public panels, attendees are engaging in discussions on artificial intelligence, climate resilience, healthcare innovation, income inequality, and women's health, among other pressing issues.
A Recap Of 2024: Last year at the conference, in a session with Mike Milken, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk spoke <a href="https://www.benzinga.com/news/24/05/38666652/tech-billionaire-elon-musk-reveals-the-3-things-that-keep-him-up-at-night-and-one-thing-that-is-his">about his top concerns</a>, including declining birth rates, threats to democracy, and the erosion of merit-based systems.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Another headline-making moment was when billionaire investor Bill Ackman came <a href="https://www.benzinga.com/news/24/05/38754804/billionaire-investor-bill-ackman-grilled-by-wall-street-executives-for-anti-dei-views-report">under sharp criticism from</a> top Wall Street executives for his opposition to diversity, equity, and inclusion initiatives during a closed-door session at the Milken Institute Global Conference.
OpenAI COO Brad Lightcap also attended the event last year and used the stage to <a href="https://www.benzinga.com/news/24/05/38661631/chatgpt-is-not-a-long-term-engagement-model-openais-top-executive-says-todays-systems-are-laughably">forecast a new wave of AI tools</a> that will act less like static oracles and more like dynamic, intelligent teammates.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/07/39842841/charlie-munger-said-getting-rich-is-harder-than-ever-but-heres-the-beauty-of-it-you-only-have-to" target="_blank" rel="noreferrer noopener">Charlie Munger Said Getting Rich Is Harder Than Ever, But Here&#8217;s ‘The Beauty Of It&#8217; — You Only Have To Do It Once</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo Courtesy: jamesonwu1972 On Shutterstock.com

Tech

NVDA

TSLA

Jensen Huang, Magic Johnson, Patrick Dempsey, Linda Yaccarino And More Bigwigs Headline Milken Global Conference 2025: What You Need To Know

<ul>
<li>Collaboration brings together FreeStyle Libre&#xAE; Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations</li>
<li>Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows</li>
</ul>
ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers.

Abbott Enters First-Of-Its-Kind Agreement To Integrate Data From Libre CGM Systems Directly Into Epic's Electronic Health Record Systems In US

In the current market session, Abbott Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) share price is at $129.36, after a 0.40% spike. Moreover, over the past month, the stock fell by 1.77%, but in the past year, increased by 22.07%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745863234_0.png" alt="Past Year Chart" />

<h3>How Does Abbott Laboratories P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 59.36 in the Health Care Equipment &amp; Supplies industry, Abbott Laboratories Inc. has a lower P/E ratio of 16.87. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745863234_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Abbott Laboratories Inc's Price Over Earnings

<ul>
<li>Long-term data from the Volt&nbsp;CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt&#x2122; PFA System</li>
<li>The 12-month results of the Volt&nbsp;CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System</li>
<li>The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting</li>
</ul>

Reported Saturday, Abbott Presents New Volt PFA System Data Highlighting Outstanding Long-Term Safety And Freedom From Arrhythmia At 12 Months

<ul>
<li>Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker</li>
<li>Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead</li>
<li>Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm</li>
</ul>

Reported Sunday, Abbott's AVEIR CSP Study Demonstrates First Successful Leadless Conduction System Pacing In Left Bundle Branch Area

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$450.00</td>
<td>$52.0K</td>
<td>100</td>
<td>4.3K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$33.3K</td>
<td>3.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>BNTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$134.3K</td>
<td>992</td>
<td>550</td>
</tr>
<tr>
<td>BHVN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$17.50</td>
<td>$26.6K</td>
<td>20</td>
<td>401</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$780.00</td>
<td>$25.9K</td>
<td>1.0K</td>
<td>384</td>
</tr>
<tr>
<td>SLNO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$25.0K</td>
<td>4.4K</td>
<td>262</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$70.00</td>
<td>$26.2K</td>
<td>897</td>
<td>233</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$70.00</td>
<td>$61.9K</td>
<td>336</td>
<td>39</td>
</tr>
<tr>
<td>MTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1180.00</td>
<td>$58.8K</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$75.00</td>
<td>$29.0K</td>
<td>10</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bearish sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 100 contract(s) at a $450.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $52.0K, with a price of $520.0 per contract. There were 100 open contracts at this strike prior to today, and today 4332 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option sweep that happens to be bullish, expiring in 273 day(s) on January 16, 2026. This event was a transfer of 34 contract(s) at a $50.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $33.3K, with a price of $980.0 per contract. There were 3960 open contracts at this strike prior to today, and today 1145 contract(s) were bought and sold. 
• For BNTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), we notice a call option sweep that happens to be bearish, expiring in 28 day(s) on May 16, 2025. This event was a transfer of 363 contract(s) at a $105.00 strike. This particular call needed to be split into 52 different trades to become filled. The total cost received by the writing party (or parties) was $134.3K, with a price of $370.0 per contract. There were 992 open contracts at this strike prior to today, and today 550 contract(s) were bought and sold. 
• Regarding BHVN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), we observe a put option trade with bearish sentiment. It expires in 28 day(s) on May 16, 2025. Parties traded 140 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $190.0 per contract. There were 20 open contracts at this strike prior to today, and today 401 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be bullish, expiring in 1 day(s) on April 17, 2025. This event was a transfer of 4 contract(s) at a $780.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $6480.0 per contract. There were 1032 open contracts at this strike prior to today, and today 384 contract(s) were bought and sold. 
• Regarding SLNO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>), we observe a call option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 50 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 4483 open contracts at this strike prior to today, and today 262 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 637 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $1050.0 per contract. There were 897 open contracts at this strike prior to today, and today 233 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a put option trade with neutral sentiment. It expires in 1 day(s) on April 17, 2025. Parties traded 38 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $61.9K, with a price of $1630.0 per contract. There were 336 open contracts at this strike prior to today, and today 39 contract(s) were bought and sold. 
• Regarding MTD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), we observe a call option trade with bearish sentiment. It expires in 182 day(s) on October 17, 2025. Parties traded 12 contract(s) at a $1180.00 strike. The total cost received by the writing party (or parties) was $58.8K, with a price of $4900.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we notice a call option trade that happens to be neutral, expiring in 336 day(s) on March 20, 2026. This event was a transfer of 5 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $5814.0 per contract. There were 10 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BHVN

BNTX

SLNO

SRPT

10 Health Care Stocks Whale Activity In Today's Session

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $132 to $142.

Price Target

Raymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $142

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $133 to $145.

Reiteration

Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $145

RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $140 to $145.

RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $145

Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $136 to $147.

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $147

Morgan Stanley analyst David Lewis maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Equal-Weight and raises the price target from $117 to $127.

Morgan Stanley Maintains Equal-Weight on Abbott Laboratories, Raises Price Target to $127

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected first-quarter <a href="https://www.benzinga.com/quote/abt/earnings">adjusted EPS results</a> on Wednesday.
Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.
"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said Robert Ford, chairman and CEO of Abbott. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."
Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.
Abbott Laboratories shares gained 0.9% to trade at $130.81 on Thursday.
These analysts made changes to their price targets on Abbott Laboratories following earnings announcement.
<ul>
<li>Jefferies analyst Matthew Taylor maintained Abbott Laboratories with a Hold and raised the price target from $135 to $137.</li>
<li>Stifel analyst Rick Wise maintained the stock with a Buy and raised the price target from $135 to $145.</li>
<li>Barclays analyst Matt Miksic maintained Abbott Laboratories with an Overweight and raised the price target from $158 to $159.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png" alt="" class="wp-image-877000" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44866413/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-3">Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Earnings

These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $158 to $159.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $159

11 analysts have shared their evaluations of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.82, a high estimate of $160.00, and a low estimate of $135.00. This upward trend is apparent, with the current average reflecting a 5.92% increase from the previous average price target of $136.73.
<img src="https://www.benzinga.com/files/images/story/2025/1744898414_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Abbott Laboratories's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $145.00&#x7C;$135.00 &#x7C; 
&#x7C;Matthew Taylor &#x7C;Jefferies &#x7C;Raises &#x7C;Hold &#x7C; $137.00&#x7C;$135.00 &#x7C; 
&#x7C;Travis Steed &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $150.00&#x7C;$133.00 &#x7C; 
&#x7C;Joanne Wuensch &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $160.00&#x7C;$135.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $154.00&#x7C;$138.00 &#x7C; 
&#x7C;Matt Miksic &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $158.00&#x7C;$149.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $135.00&#x7C;$135.00 &#x7C; 
&#x7C;Lawrence Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $136.00&#x7C;$133.00 &#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $135.00&#x7C;$130.00 &#x7C; 
&#x7C;Danielle Antalffy &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $148.00&#x7C;$146.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $135.00&#x7C;$135.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Abbott Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Abbott Laboratories's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Abbott Laboratories's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>About Abbott Laboratories</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>A Deep Dive into Abbott Laboratories's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Abbott Laboratories displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.16%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 84.1%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 21.1%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Abbott Laboratories's ROA stands out, surpassing industry averages. With an impressive ROA of 11.85%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.32.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Abbott Laboratories: Insights From 11 Analyst Reviews

Stifel analyst Rick Wise maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $135 to $145.

Stifel Maintains Buy on Abbott Laboratories, Raises Price Target to $145

Press Releases

Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib

Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology

Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races

Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes

Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery

CVKD

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Comments

Abbott Laboratories

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL